Abstract
Platinum-based antitumor agents have been effective in the treatments of many human malignancies but the ultimate success of these agents is often compromised by development of drug resistance. One mechanism associated with resistance to platinum drugs is reduced intracellular accumulation owing to impaired drug intake, enhanced outward transport, or both. Mechanisms for transporting platinum drugs were not known until recent demonstrations that import and export transporters involved in maintenance copper homeostasis are also involved in the transport of these drugs. Ctr1, the major copper influx transporter, has been convincingly demonstrated to transport cisplatin and its analogues, carboplatin, and oxaliplatin. Evidence also suggests that the two copper efflux transporters ATP7A and ATP7B regulate the efflux of cisplatin. These observations are intriguing, because conventional thinking of the inorganic physiologic chemistry of cisplatin and copper is quite different. Hence, understanding the underlying mechanistic aspects of these transporters is critically important. While the mechanisms by which hCtr1, ATP7A and ATP7B transport copper ions have been studied extensively, very little is known about the mechanisms by which these transporters shuffle platinum-based antitumor agents. This review discusses the identification of copper transporters as platinum drug transporters, the structural-functional and mechanistic aspects of these transporters, the mechanisms that regulate their expression, and future research directions that may eventually lead to improved efficacy of platinum-based-based drugs in cancer chemotherapy through modulation of their transporters’ activities.
Similar content being viewed by others
References
Kollmannsberger, C., Nichols, C., & Bokemeyer, C. (2006). Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer, 106, 1217–1226.
Boulikas, T., & Vougiouka, M. (2003). Cisplatin and platinum drug at the molecular level. Oncology Reports, 10, 1663–1682.
Giaccone, G. (2000). Clinical perspectives on platinum resistance. Drugs, 59, 9–17.
Daugaad, G., & Abildgaard, U. (1989). Cisplatin nephrotoxicity. A Review. Cancer Chemotherapy and Pharmacology, 25, 1–9.
Lokich, J., & Anderson, N. (1998). Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Annals of Oncology, 9, 12–21.
Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., & Cvitkovic, E. (2002). Cellular and molecular pharmacology of oxaliplatin. Molecular Cancer Therapeutics, 1, 227–235.
Siddik, Z. H. (2003). Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7165–7179.
Wang, D., & Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nature Rev Drug Discov, 4, 307–320.
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., & Hamilton, T. C. (1997). Increased platinum-DNA resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Research, 57, 850–856.
Gately, D. P., & Howell, S. B. (1993). Cellular accumulation of the anticancer gent cisplatin: A review. British Journal of Cancer, 67, 1171–1176.
Twentyman, P. R., Wright, K. A., Mistry, P., Kelland, L. R., & Murrer, B. A. (1992). Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Research, 52, 5674–5680.
Waud, W. R. (1987). Differential uptake of cis-diamminedichloroplatinum (II) in sensitive and resistant murine L1210 leukemia cell lines. Cancer Research, 46, 6549–6555.
Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V., Rosbe, K. W., et al. (1991). Characteristics of five human tumor cell lines and sublines resistant to cisdiamminedichloroplatinum (II). International Journal of Cancer, 47, 252–260.
Oldenburg, J., Begg, A. C., van Vugt, M. J., Ruevekamp, M., Schornagel, J. H., Pinedo, H. M., et al. (1994). Characterization of resistance mechanisms to cis-diamminedichloroplatinum (II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Research, 54, 487–493.
Kellend, L. R., Mistry, P., & Abel, G. (1992). Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatousgerm cell line. Cancer Research, 52, 1710–1716.
Metcalfe, S. A., Cain, K., & Hill, B. T. (1986). Possible mechanisms for differences in sensitivity to cisplatinum in human prostate tumor cell lines. Cancer Letters, 31, 163–169.
Song, I.-M., Savaraj, N., Siddik, Z., Liu, P., Wei, Y., Wu, C. J., et al. (2004). Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Molecular Cancer Therapeutics, 3, 1543–1549.
Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Terada, K., Furukawa, T., et al. (2000). Copper transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Research, 60, 1312–1316.
Miyamashita, H., Nitta, Y., Mori, S., Kanzaki, A., Nakayama, K., Terada, K., et al. (2003) Expression of copper transporting P-type adenotriphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncology, 39, 157–162.
Dancis, A., Haile, D., Yuan, D. S., & Klausner, R. D. (1994). The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. Journal of Biological Chemistry, 269, 25660–25667.
Dancis, A., Yuan, D. S., Haile, D., Askwith, C., Eide, D., Moehle, C., et al. (1994). Molecular characterization of a copper transport protein in S. cerevisiae: An unexpected role for copper in iron transport. Cell, 76, 398–402.
Knight, S. A., Labbe, S., Kwon, L. F., Kosman, D. J., & Thiele, D. J. (1996). A widespread transposable element masks expression of a yeast copper transport gene. Genes & Development, 10, 1917–1929.
Kampfenkel, K., Kushnir, S., Babiychuk, E., Inze, D., & Van Montagu, M. (1995). Molecular characterization of a putative, Arabidopsis thaliana copper transporter and its yeast homologue. Journal of Biological Chemistry, 270, 286479–286486.
Zhou, B., & Gitschier, J. (1997). hCtr1: A human gene for copper uptake identified by complementation in yeast. Proceedings of the National Academy of Sciences of the United States of America, 94, 7481–7486.
Lee, J., Prohaska, J. R., Dagenais, S. L., Glover, T. W., & Thiele, D. J. (2000). Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene, 254, 87–96.
Moller, L. B., Petersen, C., Lund, C., & Horn, N. (2000). Characterization of the hCtr1 gene: Genomic organization, functional expression, and identification of a highly homologous processed gene. Gene, 257, 13–22.
Lee, J., Pena, M. M., Nose, Y., & Thiele, D. J. (2002). Biochemical characterization of the human copper transporter Ctr1. Journal of Biological Chemistry, 277, 4380–4387.
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002). Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences of the United States of America, 99, 14298–14302.
Jungmann, J., Reins, H. A., Lee, J., Romeo, A., Hassett, R., Kosman, D., et al. (1993). Mac1, a nuclear regulatory protein related to Cu-dependent transcription factors is involved in Cu/Fe utilization and stress resistance in yeast. EMBO Journal, 12, 5051–5056.
Lin, X., Okuda, T., Holzer, A., & Howell, S. B. (2002). The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisae. Molecular Pharmacology, 62, 1154–1159.
Safaei, R., & Howell, S. B. (2005). Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Critical Reviews in Oncology/Hematology, 53, 13–23.
Holzer, A. K., Samimi, G., Katano, K., Naerdemann, W., Lin, X., Safaei, R., et al. (2004). The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology, 66, 817–823.
Beretta, G. L., Gatti, L., Tinelli, S., Corna, E., Colangelo, D., Zunino, F., et al. (2004). Cellular pharmacology of cisplatin in relation to the expression of human copper transporter Ctr1 in different pairs of cisplatin-sensitive and -resistant cells. Biochemical Pharmacology, 68, 283–291.
Puig, S., & Thiele, D. J. (2002). Molecular mechanisms of copper uptake and distribution. Current Opinion in Chemical Biology, 6, 171–180.
Klomp, A. E., Juijin, J. A., van der Gun, L. T., van den Berg, I. E., Berger, R., & Klomp, L. W. (2003). The N-terminus of the human copper transporter1 (hCtr1) is localized extracellularly and interacts with itself. Biochemical Journal, 370, 881–889.
Aller, S. G., Eng, E. T., De Feo, C. J., & Unger, U. M. (2004). Eukaryotic CTR copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function. Journal of Biological Chemistry, 279, 53435–53441.
Aller, S. G., & Unger, V. M. (2006). Projection structure of the human copper transporter Ctr1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture. Proceedings of the National Academy of Sciences of the United States of America, 103, 3627–3632.
Eisses, J. F., & Kaplan, J. H. (2002). Molecular characterization of hCtr1, the human copper uptake protein. Journal of Biological Chemistry, 277, 29162–29171.
Puig, S., Lee, J., Lau, M., & Thiele, D. J. (2002). Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. Journal of Biological Chemistry, 277, 26021–26030.
Guo, Y., Smith, K., & Patris, M. J. (2004). Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter requirement for the extracellular methionine-rich clusters. Journal of Biological Chemistry, 279, 46393–46399.
Eisses, J. F., & Kaplan, J. H. (2005). The mechanism of copper uptake mediated by human Ctr1. A mutational analysis. Journal of Biological Chemistry, 280, 37159–37168.
Arnesano, F., Banci, L., Bertini, I., Cantini, F., Ciofi-Baffoni, S., Huffman, D. L., et al. (2001). Characterization of the binding interface between the copper chaperone Atx1 and the first cytosolic domain of Ccc2 ATPase. Journal of Biological Chemistry, 276, 41365–41376.
Vulpe, C., Levinson, B., Whitney, S., Packman, S., & Gitschier, J. (1993). Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nature Genetics, 3, 7–13.
Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. M., Forbes, J. R., & Cox, D. W. (1993). The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genetics, 5, 327–337.
Camakaris, J., Voskoboinik, I., & Mercer, J. F. (1999). Molecular mechanisms of copper homeostasis. Biochemical and Biophysical Research Communications, 261, 225–232.
DiDonato, M., & Sarkar, B. (1997). Copper transport and its alterations in Menkes and Wilson diseases. Biochimica et Biophysica Acta, 1360, 3–16.
Prohaska, J. R., & Gybina, A. A. (2004). Intracellular copper transport in mammals. Journal of Nutrition, 134, 1003–1006.
Hellman, N. E., & Gitlin, J. D. (2002). Ceruloplasmin metabolism and function. Annual Review of Nutrition, 22, 439–458.
Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Tarada, K., Furukawa, T., et al. (2000). Copper transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Research, 60, 1313–1316.
Nakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., et al. (2004). Prognostic value of the cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clinical Cancer Research, 10, 2804–2811.
Ohbu, M., Ogawa, K., Konno, S., Kanzaki, A., Terada, K., Sugiyama, T., et al. (2003). Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. Cancer Letters, 189, 33–38.
Samimi, S., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., et al. (2004). Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clinical Cancer Research, 10, 4661–4669.
Samimi, G., Varki, N. M., Wilczynski, S., Safaei, R., Alberts, D. S., & Howell, S. B. (2003). Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clinical Cancer Research, 9, 5853–5859.
Strausak, D., La Fontaine, S., Hill, J., Firth, S. D., Lockhart, P. J., & Mercer, J. F. R. (1999). The role of GMXCXXC metal binding sites in the copper-induced redistribution of the Menkes protein. Journal of Biological Chemistry, 274, 11170–11177.
Achila, D., Banci, L., Bertini, I., Bunce, J., Ciofi-Baffoni, S., & Huffman, D. L. (2006). Structure of human Wilson protein domains 5 and 6 and their interplay with domain 4 and the copper chaperone HAH1 in copper uptake. Proceedings of the National Academy of Sciences of the United States of America, 103, 5729–5734.
Banci, L., Bertini, I., Cantini, F., Chasapis, C. T., Hadjiliadis, N., & Rosato, A. (2005). A NMR study of the interaction of a three domain construct of ATP7A with copper (I) and copper (I)-HAH1. Journal of Biological Chemistry, 280, 38259–38263.
Francis, M. J., Jones, E. E., Levy, E. R., Ponnambalam, S., Chelly, J., & Monaco, A. (1998). A Golgi localization signal identified in the Menkes recombinant protein. Human Molecular Genetics, 7, 1245–1252.
Petris, M. J., & Mercer, J. F. (1999). The menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Human Molecular Genetics, 8, 2107–2115.
Wernimont, A. K., Huffman, D. L., Lamb, A. L., O’Halloran, T. V., & Rosenzweig, A. C. (2000). Structural basis for copper transfer by the metallochaperone for the Menkes/Wilson disease proteins. Nature Structural Biology, 7, 766–771.
Rutherford, J. C., & Bird, A. J. (2004). Metal-responsive transcriptions that regulate iron, zinc, and copper homeostasis in eukaryotic cells. Eukaryotic Cell 3, 1–13.
Graden, J. A., & Winge, D. R. (1997). Copper mediated repression of the activation domain in the yeast Mac1p transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 94, 5550–5555.
Serpe, M., Joshi, A., & Kosman, D. J. (1999). Structure-function analysis of the protein-binding domains of Mac1p, a copper-dependent transcriptional activator of copper uptake in Saccharomyces cerevisiae. Journal of Biological Chemistry, 274, 29211–29219.
Jensen, L. T., & Winge, D. R. (1998). Identification of a copper-induced intramolecular inteaction in the transcription factor Mac1 from Saccharomyces cerevisiae. EMBO Journal, 17, 5400–5408.
Dameron, C. T., Winge, D. R., George, G. N., Sansone, M., Hu, S., & Hamer, D. (1991). A copper-thiolate polynuclear cluster in the ACE1 transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 88, 6127–6131.
Butt, T. R., Sternberg, E. J., Gorman, J. A., Clark, P., Hamer, D., Rosenberg, M., et al. (1984). Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proceedings of the National Academy of Sciences of the United States of America, 81, 3332–3336.
Ooi, C. E., Rabinovich, E., Dancis, A., Bonifacino, J. S., & Klausner, R. D. (1996). Copper-dependent degradation of the Saccharomyces cerevisiae plasma membrane copper transporter Ctr1p in the apparent absence of endocytosis. EMBO Journal 15, 3515–3523.
Yonkovich, J., McKenndry, R., Shi, X., & Zhu, Z. (2002). Copper ion-sensing transcription factor Mac1p post-translationally controls the degradation of its target gene product Ctr1p. Journal of Biological Chemistry, 277, 23981–23984.
Zhou, H., Cadigan, K. M., & Thiele, D. J. (2003). A copper-regulated transporter required for copper acquisition, pigmentation, and specific stages of development in Drosophila melanogaster. Journal of Biological Chemistry, 278, 48210–48218.
Selvaraj, A., Balamurugan, K., Yepiskoposyan, H., Zhou, H., Egli, D., Georgiev, O., et al. (2005). Metal-responsive transcription factor (MTF-1) handles both extremes, copper load and copper starvation, by activating different genes. Genes & Development, 19, 891–896.
Balamurugan, K., & Schaffner, W. (2006) Copper homeostasis in eukaryotes:Teetering on a tightrope. Biochimica et Biophysica Acta, 1763, 737–746.
Giedroc, D. P., Chen, X., & Apuy, J. L. (2001). Metal response element (MRE)-binding transcription factor-1(MTF-1): Structure, function, and regulation. Antioxidants and Redox Signalling, 3, 577–596.
Li, Y., Kimura, T., Laity, J. H., & Andrews, G. K. (2006). The zinc-sensing mechanism of mouse MTF-1 involves linker peptides between the zinc fingers. Molecular and Cellular Biology, 26, 5580–5587.
Petris, M. J., Smith, K., Lee, J., & Thieles, D. J. (2003). Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. Journal of Biological Chemistry, 278, 9639–9646.
Guo, Y., Smith, K., Lee, J., Thiele, D. J., Patris, & M. J. (2004). Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. Journal of Biological Chemistry, 279, 17428–17483.
Eisses, J. F., & Kaplan, J. H. (2002). Molecular characterization of hCtr1, the human copper uptake protein. Journal of Biological Chemistry, 277, 29162–29171.
Eisses, J. F., Chi, Y., & Kaplan, J. H. (2005). Stable plasma membrane levels of hCTR1 mediate cellular copper uptake. Journal of Biological Chemistry, 280, 9635–9639.
Lee, J., Prohaska, J. R., Dagenais, S. L., Glover, T. W., & Thiele, D. J. (2000). Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene, 254, 87–96.
Finney, L. A., & O’Halloran, T. V. (2003). Transition metal speciation in the cell: insights from the chemistry of metal ion receptions. Science, 300, 931–936.
Harrison, M. D., Jones, C. E., Solioz, M., & Dameron, C. T. (2000). Intracellular copper routing: The role of copper chaperones. Trends in Biochemical Sciences, 25, 29–32.
Cobine, P. A., Pierrel, F., & Winge, D. R. (2006) Copper trafficking to the mitochondrion and assembly of copper metalloenzymes. Biochimica et Biophysica Acta, 1763, 759–772.
Mesecke, N., Terziyska, N., Kozany, C., Baumann, F., Neupert, W., Hell, K., et al. (2005). A disulfide relay system in the intermembrane space of mitochondria that mediates protein import. Cell, 121, 1059–1069.
Arnesano, F., Balatri, E., Banci, L., Bertini, I., & Winge, D. R. (2005). Folding studies of Cox 17 reveal an important interplay of cysteine oxidation and copper binding. Structure, 13, 13–722.
Schmidt, P. J., Kunst, C., & Culotta, V. C. (2000). Copper activation of superoxide dismutase 1 (SOD1) in vivo. Role for protein-protein interactions with the copper chaperone for SOD1. Journal of Biological Chemistry, 275, 33771–33776.
Wong, P. C., Waggoner, D., Subramaniam, J. R., Tessarollo, L., Bartnikas, T. B., Culotta, V. C., et al. (2000). Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proceedings of the National Academy of Sciences of the United States of America, 97, 2886–2891.
Culotta, V. C., Klomp, L. W., Strain, J., Casareno, R. L., Krems, B., & Gitlin, J. D. (1997). The copper chaperone for superoxide dismutase. Journal of Biological Chemistry, 272, 23469–23472.
Lamb, A. L., Torres, A. S., O’Halloran, T. V., & Rosenzweig, A. C. (2001). Heterodimeric structure of superoxide dismutase in complex with its metallochaperone. Nature Structural Biology, 8, 751–755.
Molenaar, C., Teuben, J.-M., Heetebrij, R. J., Tanke, H. J., & Reedijk, J. (2000). New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy. Journal of Biological Inorganic Chemistry, 5, 655–665.
Safaei, R., Katano, K., Larson, B. J., Samimi, G., Holzer, A. K., Naerdemann, W., et al. (2005). Intracellular localization and trafficking of fluoroscein-labeled cisplatin in human ovarian carcinoma cells. Clinical Cancer Research, 11, 756–767.
Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., et al. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer lines to cisplatin. Cancer Research, 51, 3237–3242.
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988). Overexpression of metallothionein confers resistance to anticancer agents. Science, 241, 1813–1815.
Smith, D. J., Jaggi, M., Zhang, W., Galich, A., Du, C., Sterrett, S. P., et al. (2006). Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology, 67, 1341–1347.
Waalkes, M. P., Liu, J., Kasprzak, K. S., & Diwan, B. A. (2006). Hypersusceptibility to cisplatin carcinogenicity in metallothionein-III double knockout mice: Production of hepatocellular carcinoma at clinically relevant doses. International Journal of Cancer, 119, 28–32.
Freedman, J. H., Ciriolo, M. R., & Peisach, J. (1989). The role of glutathione in copper metabolism and toxicity. Journal of Biological Chemistry, 264, 5598–5605.
Steineback, O. M., & Wolterbeek, H. T. (1994). Role of cytosolic copper, metallothionein and glutathione in copper toxicity in rat hepatoma tissue culture cells. Toxicology, 92, 75–90.
Circiolo, M. R., Desideri, M., Paci, M., & Rotilo, G. (1990). Reconstitution of Cu, Zn-superoxidedismutase by the Cu(I) glutathione complex. Journal of Biological Chemistry, 265, 11030–11034.
Lamb, A. L., O’Halloran, T. V., & Rosenzweig, A. C. (2000). Structural basis for copper transfer by the metalloperone for the Menkes/Wilson disease proteins. Nature Structural Biology, 7, 766–771.
Siddik, Z. H. (2002). Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treatment and Research, 112, 263–284.
Ishikawa, T., Bao, J. J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D., et al. (1996). Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. Journal of Biological Chemistry, 271, 4981–4988.
Ishikawa, T., & Ali-Osman, F. (1993). Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. Journal of Biological Chemistry, 268, 20116–20125.
Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., & Kawakami, M. (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Research, 56, 4124–4129.
Liedert, B., Materna, V., Schadendorf, G. L., Thomale, J., & Lage, H. (2003). Overexpression of cMOAT(MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Journal of Investigative Dermatology, 121, 172–176.
Cui, Y., Konig, J., Buchholz, J. K., Spring, H., Leier, I., & Keppler, D. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Molecular Pharmacology, 55, 929–937.
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., et al. (1997). A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhance drug sensitivity in human hepatic cancer cells. Cancer Research, 57, 5475–5479.
Minamino, T., Tamai, M., Itoh, Y., Tatsumi, Y., Nomura, M., Yokogawa, K., et al. (1999). In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT). Japanese Journal of Cancer Research, 90, 1171–1178.
Ishikawa, T., Nakagawa, H., & Kuo, M. T. (2007). The GS-X pump/multidrug resistance protein (MRP): Role of glutathione in their function and gene regulation. Nova Scotia Review (in press).
Chauhan, S. S., Liang, X. J., Su, A. W., Pai-Panandiker, A., Shen, D. W., Hanover, J. A., et al. (2003). Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. British Journal of Cancer, 88, 1327–1334.
Liang, X. J., Mukherjee, S., Shen, D. W., Maxfield, F. R., & Gottesman, M. M. (2006). Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Research, 66, 2346–2353.
Lee, J., Prohaska, J. R., & Thiele, D. J. (2001). Essential role for mammalian copper transporter Ctr1 copper homeostasis and embryonic development. Proceedings of the National Academy of Sciences of the United States of America, 98, 6842–6847.
Kuo, Y. M., Zhou, B., Cosco, D., & Gitschier, J. (2001). The copper transporter Ctr1 provides an essential function in mammalian embryonic development. Proceedings of the National Academy of Sciences of the United States of America, 98, 6836–6841.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuo, M.T., Chen, H.H.W., Song, IS. et al. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 26, 71–83 (2007). https://doi.org/10.1007/s10555-007-9045-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-007-9045-3